Sung Mo Choi

Title: Innovations of Sung Mo Choi in Drug Delivery Systems.

Introduction

Sung Mo Choi is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of drug delivery systems, particularly through his innovative patent related to cyclotriphosphazene compounds. His work focuses on enhancing the efficacy and safety of drug delivery methods, especially for protein drugs.

Latest Patents

Sung Mo Choi holds a patent for "Dendritic oligopeptide-grafted cyclotriphosphazene, a process for the preparation thereof and a drug delivery system containing the same." This invention involves a cyclotriphosphazene represented by Formula 1, which is prepared by introducing a dendritic tetrapeptide and a hydrophilic polyethylene glycol into a cyclotriphosphazene ring. The resulting compound can form a strong molecular hydrogel at a very low concentration of 2 w/w % or less. The hydrogel exhibits biodegradability, thermosensitivity around body temperature, and biocompatibility with protein drugs. It also allows for sustained drug release without any burst effect in the early stages.

Career Highlights

Sung Mo Choi is associated with Cnpharm Co. Ltd., where he continues to develop innovative solutions in drug delivery. His work has the potential to revolutionize how medications, particularly protein drugs, are administered, ensuring better patient outcomes.

Collaborations

He has collaborated with notable colleagues, including Youn Soo Sohn and Yong Joo Jun, to advance research and development in his field.

Conclusion

Sung Mo Choi's contributions to drug delivery systems through his innovative patent highlight the importance of research in improving medical treatments. His work exemplifies the intersection of science and technology in enhancing healthcare solutions.